Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
09 déc. 2024 07h00 HE
|
Kura Oncology, Inc.
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients...
Kura Oncology to Host Virtual Investor Event on December 9, 2024
02 déc. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
25 nov. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
20 nov. 2024 17h00 HE
|
Kura Oncology, Inc.
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – –...
Kura Oncology Reports Third Quarter 2024 Financial Results
07 nov. 2024 16h05 HE
|
Kura Oncology, Inc.
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in...
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
05 nov. 2024 09h09 HE
|
Kura Oncology, Inc.
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th – – Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r...
Kura Oncology to Report Third Quarter 2024 Financial Results
31 oct. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
24 oct. 2024 07h30 HE
|
Kura Oncology, Inc.
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib...
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
23 oct. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
30 sept. 2024 18h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...